<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>OXYTOCIN- oxytocin injection, solution </strong><br>APP Pharmaceuticals, LLC<br></p></div>
<h1>Oxytocin Injection USP</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="bab48f7a-6ae4-409f-ac6b-91612d891568"></a><a name="section-1"></a><p></p>
<h1></h1>
<p class="First"><span class="Italics"><span class="Emphasis">(SYNTHETIC)</span></span></p>
<p><span class="Italics"><span class="Emphasis">FOR INTRAVENOUS INFUSION OR INTRAMUSCULAR USE</span></span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="a6c1952c-adaa-41a2-853c-fbfb48ef308e"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Each mL of Oxytocin Injection, USP (synthetic), intended for intravenous infusion or intramuscular injection, possesses an oxytocic activity equivalent to 10 USP Oxytocin Units and contains chlorobutanol anhydrous (chloral derivative) 0.5%.  This product may contain up to 12.5% decomposition products/impurities.  Oxytocin injection (synthetic) is a sterile, clear, colorless solution of oxytocin in Water for Injection prepared by synthesis.  Acetic acid may have been added for pH adjustment (pH 3.0-5.0).  The structural formula is:</p>
<p> </p>
<p><img alt="structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c7fd585a-99b7-4309-b003-a6cbef05372c&amp;name=oxytocin-injection-usp-figure-1-oxytocin-structure.jpg"> </p>
<br>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="f2de42ff-0cb9-47fd-8c36-cfe51063c23f"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Oxytocin injection (synthetic) acts on the smooth muscle of the uterus to stimulate contractions; response depends on the uterine threshold of <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">excitability</span>.  It exerts a selective action on the smooth musculature of the uterus, particularly toward the end of pregnancy, during labor and immediately following delivery.  Oxytocin stimulates rhythmic contractions of the uterus, increases the frequency of existing contractions and raises the tone of the uterine musculature.  Synthetic oxytocin does not possess the cardiovascular effects, such as elevation of blood pressure, as exhibited by vasopressin found in posterior pituitary injection.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="c0dcab60-3469-49c7-9681-556baab45ed8"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<table><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule"> <br>
                                                                                               <span class="Bold"><span class="Emphasis">IMPORTANT NOTICE:</span></span><p class="First"> </p>
            Oxytocin Injection, USP (synthetic) is indicated for the medical rather than the elective induction of labor.  Available data and information are inadequate to define the benefits to risks considerations in the use of the drug product for elective induction.  Elective induction of labor is defined as the initiation of labor for convenience in an individual with a term pregnancy who is free of medical indications.<br>
              <br>
</td></tr></tbody></table>
<br><div class="Section" data-sectionCode="34067-9">
<a name="c61146ff-3ff7-4794-afc8-3a0d6b23ea33"></a><a name="section-4.1"></a><p></p>
<h2>Antepartum</h2>
<p class="First">Oxytocin injection (synthetic) is indicated for the initiation or improvement of uterine contractions, where this is desirable and considered suitable, in order to achieve early vaginal delivery for fetal or maternal reasons.  It is indicated for (1) induction of labor in patients with a medical indication for the initiation of labor, such as Rh problems, maternal <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, pre-<span class="product-label-link" type="condition" conceptid="443700" conceptname="Eclampsia">eclampsia</span> at or near term, when delivery is in the best interest of mother and fetus or when membranes are prematurely ruptured and delivery is indicated; (2) stimulation or reinforcement of labor, as in selected cases of uterine inertia; (3) adjunctive therapy in the management of incomplete or inevitable abortion.  In the first trimester, curettage is generally considered primary therapy.  In second trimester abortion, oxytocin infusion will often be successful in emptying the uterus.  Other means of therapy, however, may be required in such cases.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="bfb2f88d-11ff-4f5a-bcf7-82d4468a742e"></a><a name="section-4.2"></a><p></p>
<h2>Postpartum</h2>
<p class="First">Oxytocin injection (synthetic) is indicated to produce uterine contractions during the third stage of labor and to control postpartum <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="a5ebce41-46a5-47cb-9555-aa23bb92ca64"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Oxytocin injection (synthetic) is contraindicated in any of the following conditions:</p>
<ul>
<li>Significant cephalopelvic disproportion;</li>
<li>Unfavorable fetal positions or presentations which are undeliverable without conversion prior to delivery, i.e., transverse lies;</li>
<li>In obstetrical emergencies where the benefit-to-risk ratio for either the fetus or the mother favors <span class="product-label-link" type="condition" conceptid="4121697" conceptname="Surgery">surgical intervention</span>;</li>
<li>In cases of <span class="product-label-link" type="condition" conceptid="73268" conceptname="Fetal distress affecting management of mother">fetal distress</span> where delivery is not imminent;</li>
<li>Prolonged use in uterine inertia or severe toxemia;</li>
<li>Hypertonic uterine patterns;</li>
<li>Patients with <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to the drug;</li>
<li>Induction or augmentation of labor in those cases where vaginal delivery is contraindicated, such as cord presentation or prolapse, total placenta previa, and vasa previa.</li>
</ul>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="ba2de0f6-114c-46c8-817a-d5374aba2728"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">Oxytocin injection (synthetic) when given for induction or stimulation of labor, must be administered only by the intravenous route and with adequate medical supervision in a hospital.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="fa010b4a-a51d-49ed-b23b-6dc4051db20c"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42232-9">
<a name="e0a3e88d-7b27-4273-89e6-9b985bc5c584"></a><a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">All patients receiving intravenous oxytocin must be under continuous observation by trained personnel with a thorough knowledge of the drug and qualified to identify complications.  A physician qualified to manage any complications should be immediately available.</p>
<p>When properly administered, oxytocin should stimulate uterine contractions similar to those seen in normal labor.  Overstimulation of the uterus by improper administration can be hazardous to both mother and fetus.  Even with proper administration and adequate supervision, hypertonic contractions can occur in patients whose uteri are hypersensitive to oxytocin.</p>
<p>Except in unusual circumstances, oxytocin should not be administered in the following conditions: <span class="product-label-link" type="condition" conceptid="439128" conceptname="Extreme immaturity">prematurity</span>, borderline cephalopelvic disproportion, previous major surgery on the cervix or uterus including Caesarean section, overdistention of the uterus, grand multiparity or invasive cervical carcinoma.  Because of the variability of the combinations of factors which may be present in the conditions above, the definition of ‘‘unusual circumstances’’ must be left to the judgement of the physician.  The decision can only be made by carefully weighing the potential benefits which oxytocin can provide in a given case against rare but definite potential for the drug to produce <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">hypertonicity</span> or tetanic spasm.</p>
<p>Maternal <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> due to <span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">hypertensive episodes</span>, <span class="product-label-link" type="condition" conceptid="432923" conceptname="Subarachnoid hemorrhage">subarachnoid hemorrhage</span>, rupture of the uterus and <span class="product-label-link" type="condition" conceptid="4079844" conceptname="Fetal death">fetal deaths</span> due to various causes have been reported associated with the use of parenteral oxytocic drugs for induction of labor and for augmentation in the first and second stages of labor.</p>
<p>Oxytocin has been shown to have an intrinsic antidiuretic effect, acting to increase water reabsorption from the glomerular filtrate.  Consideration should, therefore, be given to the possibility of <span class="product-label-link" type="condition" conceptid="4215499" conceptname="Water intoxication syndrome">water intoxication</span>, particularly when oxytocin is administered continuously by infusion and the patient is receiving fluids by mouth.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="ac51473e-9c7d-4cae-abe6-26266a9b4afc"></a><a name="section-7.2"></a><p></p>
<h2>Drug Interactions<br>
</h2>
<p class="First">Severe <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> has been reported when oxytocin was given three to four hours following <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> administration of a vasoconstrictor in conjunction with caudal block anesthesia.  Cyclopropane anesthesia may modify oxytocin’s cardiovascular effects, so as to produce unexpected results such as <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>.  Maternal <span class="product-label-link" type="condition" conceptid="4171683" conceptname="Sinus bradycardia">sinus bradycardia</span> with abnormal atrioventricular rhythms has also been noted when oxytocin was used concomitantly with cyclopropane anesthesia.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="c926db59-0fcb-44e4-8031-3951d4d47aca"></a><a name="section-7.3"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility<br>
</h2>
<p class="First">There are no animal or human studies on the carcinogenicity and mutagenicity of this drug, nor is there any information on its effect on fertility.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="ddfe2844-4c74-491b-8663-a6a4787e3dfb"></a><a name="section-7.4"></a><p></p>
<h2>Pregnancy Category C.<br>
</h2>
<p class="First">There are no known indications for use of oxytocin in the first and second trimester of pregnancy other than in relation to spontaneous or induced abortion.  Based on the wide experience with this drug and its chemical structure and pharmacological properties, it would not be expected to present a risk of fetal abnormalities when used as indicated.</p>
<p>Nonteratogenic Effects—See <span class="Bold"><span class="Emphasis"><a href="#a384191e-c75d-413a-8147-2d94707a96f0">ADVERSE REACTIONS</a></span></span> in the fetus or infant.</p>
<p>Labor and Delivery—See <span class="Bold"><span class="Emphasis"><a href="#c0dcab60-3469-49c7-9681-556baab45ed8">INDICATIONS AND USAGE</a></span></span>.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="bc9b244c-a5c2-4ad8-ac9d-23cbc58afaa3"></a><a name="section-7.5"></a><p></p>
<h2>Nursing Mothers<br>
</h2>
<p class="First">It is not known whether this drug is excreted in human milk.  Because many drugs are excreted in human milk, caution should be exercised when oxytocin is administered to a nursing woman.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="a384191e-c75d-413a-8147-2d94707a96f0"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">The following adverse reactions have been reported in the mother:</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic reaction</span></li>
<li><span class="product-label-link" type="condition" conceptid="443929" conceptname="Postpartum hemorrhage">Postpartum hemorrhage</span></li>
<li><span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Cardiac arrhythmia</span></li>
<li>Fatal <span class="product-label-link" type="condition" conceptid="4083191" conceptname="Afibrinogenemia">afibrinogenemia</span></li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></li>
<li><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></li>
<li><span class="product-label-link" type="condition" conceptid="4008580" conceptname="Ventricular bigeminy">Premature ventricular contractions</span></li>
<li><span class="product-label-link" type="condition" conceptid="4131053" conceptname="Pelvic hematoma">Pelvic hematoma</span></li>
</ul>
<p>Excessive dosage or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to the drug may result in uterine <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">hypertonicity</span>, spasm, tetanic contraction or rupture of the uterus.</p>
<p>The possibility of increased blood loss and <span class="product-label-link" type="condition" conceptid="4083191" conceptname="Afibrinogenemia">afibrinogenemia</span> should be kept in mind when administering the drug.</p>
<p>Severe <span class="product-label-link" type="condition" conceptid="4215499" conceptname="Water intoxication syndrome">water intoxication</span> with <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> has occurred, and is associated with a slow oxytocin infusion over a 24-hour period.  Maternal <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> due to oxytocin-induced <span class="product-label-link" type="condition" conceptid="4215499" conceptname="Water intoxication syndrome">water intoxication</span> has been reported.</p>
<p>The following adverse reactions have been reported in the fetus or infant:</p>
<p>Due to induced uterine mobility:</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span></li>
<li><span class="product-label-link" type="condition" conceptid="4008580" conceptname="Ventricular bigeminy">Premature ventricular contractions</span> and other <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span></li>
<li>Permanent CNS or <span class="product-label-link" type="condition" conceptid="4080670" conceptname="Brain damage">brain damage</span></li>
<li><span class="product-label-link" type="condition" conceptid="4079844" conceptname="Fetal death">Fetal death</span></li>
</ul>
<p>Due to use of oxytocin in the mother:</p>
<ul>
<li>Neonatal <span class="product-label-link" type="condition" conceptid="374025" conceptname="Retinal hemorrhage">retinal hemorrhage</span></li>
<li>Low Apgar scores at five minutes</li>
<li><span class="product-label-link" type="condition" conceptid="195064" conceptname="Perinatal jaundice due to hepatocellular damage">Neonatal jaundice</span></li>
</ul>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="fec61377-4cac-4aa0-8e02-7694c83b113e"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Overdosage with oxytocin injection (synthetic) depends essentially on uterine <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactivity</span> whether or not due to <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to this agent.  Hyperstimulation with strong (hypertonic) or prolonged (tetanic) contractions, or a resting tone of 15 to 20 mm H<span class="Sub">2</span>O or more between contractions can lead to tumultuous labor, <span class="product-label-link" type="condition" conceptid="195328" conceptname="Rupture of uterus before onset of labor">uterine rupture</span>, cervical and vaginal <span class="product-label-link" type="condition" conceptid="443419" conceptname="Laceration - injury">lacerations</span>, <span class="product-label-link" type="condition" conceptid="443929" conceptname="Postpartum hemorrhage">postpartum hemorrhage</span>, uteroplacental <span class="product-label-link" type="condition" conceptid="4131044" conceptname="Hypoperfusion">hypoperfusion</span> and variable deceleration of fetal heart, fetal <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span>, <span class="product-label-link" type="condition" conceptid="4105765" conceptname="Hypercapnia">hypercapnia</span> or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.  <span class="product-label-link" type="condition" conceptid="4215499" conceptname="Water intoxication syndrome">Water intoxication</span> with <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, which is caused by the inherent antidiuretic effect of oxytocin, is a serious complication that may occur if large doses (40 to 50 milliunits/minute) are infused for long periods.  Management consists of immediate discontinuation of oxytocin, and symptomatic and supportive therapy.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="d6bab53d-a61b-481e-9c91-becd5a34b492"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Dosage of oxytocin is determined by uterine response.  The following dosage information is based upon the various regimens and indications in general use.</p>
<div class="Section" data-sectionCode="34068-7">
<a name="a4804eff-c0eb-491b-be99-530fc4a1ac9f"></a><a name="section-10.1"></a><p></p>
<h2>Induction or Stimulation of Labor<br>
</h2>
<p class="First">Intravenous infusion (drip method) is the only acceptable method of administration for the induction or stimulation of labor.</p>
<p>Accurate control of the rate of infusion flow is essential.  An infusion pump or other such device and frequent monitoring of strength of contractions and fetal heart rate are necessary for the safe administration of oxytocin for the induction or stimulation of labor.  If uterine contractions become too powerful, the infusion can be abruptly stopped, and oxytocic stimulation of the uterine musculature will soon wane.</p>
<p>An intravenous infusion of a non-oxytocin containing solution should be started.  Physiologic electrolyte solutions should be used except under unusual circumstances.</p>
<p>To prepare the usual solution for intravenous infusion–one mL (10 units) is combined aseptically with 1,000 mL of a non-hydrating diluent.</p>
<p>The combined solution, rotated in the infusion bottle to insure thorough mixing, contains 10 mU/mL.  Add the container with dilute oxytocic solution to the system through the use of a constant infusion pump or other such device to control accurately the rate of infusion.</p>
<p>The initial dose should be no more than 1 to 2 mU/min.  The dose may be gradually increased in increments of no more than 1 to 2 mU/min., until a contraction pattern has been established which is similar to normal labor.</p>
<p>The fetal heart rate, resting uterine tone, and the frequency, duration, and force of contractions should be monitored.</p>
<p>The oxytocin infusion should be discontinued immediately in the event of uterine <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactivity</span> or <span class="product-label-link" type="condition" conceptid="73268" conceptname="Fetal distress affecting management of mother">fetal distress</span>.   Oxygen should be administered to the mother.  The mother and fetus must be evaluated by the responsible physician.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="fbb76be9-242d-4043-9e72-07cd50a348b1"></a><a name="section-10.2"></a><p></p>
<h2>Control of Postpartum <span class="product-label-link" type="condition" conceptid="195876" conceptname="Hematometra">Uterine Bleeding</span><br>
</h2>
<p class="First"><span class="Italics"><span class="Emphasis">Intravenous Infusion</span></span> (<span class="Italics"><span class="Emphasis">Drip Method</span></span>)—To control postpartum <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, 10 to 40 units of oxytocin may be added to 1,000 mL of a nonhydrating diluent and run at a rate necessary to control <span class="product-label-link" type="condition" conceptid="4127206" conceptname="Uterus relaxed">uterine atony</span>.</p>
<p><span class="Italics"><span class="Emphasis">Intramuscular Administration</span></span>—1 mL (10 units) of oxytocin can be given after delivery of the placenta.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="f795b031-47ca-4733-8ff0-3d7963b58274"></a><a name="section-10.3"></a><p></p>
<h2>Treatment of Incomplete or Inevitable Abortion<br>
</h2>
<p class="First">Intravenous infusion with physiologic saline solution, 500 mL, or 5% dextrose in physiologic saline solution to which 10 units of oxytocin have been added should be infused at a rate of 20 to 40 drops/minute.</p>
<p>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="ffdeee07-2ec0-4870-8245-ff26553230e5"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First"><span class="Bold"><span class="Emphasis">Oxytocin Injection, USP (synthetic) is supplied as follows:</span></span> 
</p>
<table><tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First"><span class="Bold"><span class="Emphasis">Product</span></span></p>
<p><span class="Bold"><span class="Emphasis">No.</span></span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First"><span class="Bold"><span class="Emphasis">NDC</span></span></p>
<p><span class="Bold"><span class="Emphasis">No.</span></span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="bottom"><p class="First"><span class="Bold"><span class="Emphasis">Strength</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="bottom"><p class="First"><span class="Bold"><span class="Emphasis">Volume</span></span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">91201<span class="Sup">*</span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">63323-012-01</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">10 USP Units/mL</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">1 mL fill in a 3 mL vial, packaged in trays of 25.</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">1210</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">63323-012-10</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">10 USP Units/mL</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">10 mL fill in a 10 mL multiple dose vial, packaged in trays of 25.</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">501230<span class="Sup">†    
            </span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">63323-012-30      </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">10 USP Units/mL      </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">30 mL fill in a 30 mL multiple dose vial, packaged in trays of 10.</p></td>
</tr>
</tbody></table>
<p> <span class="Sup">*</span>Packaged in a plastic vial.</p>
<p><span class="Sup">†</span>Vial stoppers do not contain natural rubber latex.</p>
<p>
Discard unused portion.</p>
<p>
Use only if solution is clear and seal intact.</p>
<p>
Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].</p>
<p>
Do not permit to freeze.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="a9b31913-75dd-4d51-9a19-5c429f0ecf74"></a><a name="section-12"></a><p></p>
<h1></h1>
<p class="First"><img alt="logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c7fd585a-99b7-4309-b003-a6cbef05372c&amp;name=oxytocin-injection-usp-figure-2-add_band_logo.jpg"> </p>
<p>45789F</p>
<p>Revised: December 2007</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ad00e3e2-663b-479d-b4f3-ec2198819c51"></a><a name="section-13"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold"><span class="Emphasis">PACKAGE LABEL - PRINCIPAL DISPLAY - Oxytocin 10 mL Multiple Dose Vial Label<br></span></span></p>
<p><span class="Bold"><span class="Emphasis">Oxytocin Injection, USP</span></span></p>
<p><span class="Bold"><span class="Emphasis">(Synthetic)</span></span></p>
<p><span class="Bold"><span class="Emphasis">10 USP Units/mL</span></span></p>
<p>For IV Infusion or IM Use</p>
<p><span class="Bold"><span class="Emphasis">10 mL</span></span> Multiple Dose Vial</p>
<p>Rx only</p>
<p> </p>
<p><img alt="1210-vial" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c7fd585a-99b7-4309-b003-a6cbef05372c&amp;name=oxytocin-injection-usp-figure-3-1210-vial.jpg"> </p>
<br>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>OXYTOCIN 		
					</strong><br><span class="contentTableReg">oxytocin injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:63323-012</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS, INTRAMUSCULAR</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>OXYTOCIN</strong> (OXYTOCIN) </td>
<td class="formItem">OXYTOCIN</td>
<td class="formItem">10 [USP'U]  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CHLOROBUTANOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ACETIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:63323-012-01</td>
<td class="formItem">25  in 1 TRAY</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1 mL in 1 VIAL</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:63323-012-10</td>
<td class="formItem">25  in 1 TRAY</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">10 mL in 1 VIAL, MULTI-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:63323-012-30</td>
<td class="formItem">10  in 1 TRAY</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem"></td>
<td class="formItem">30 mL in 1 VIAL, MULTI-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA018248</td>
<td class="formItem">08/10/2000</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>APP Pharmaceuticals, LLC
							(608775388)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">APP Pharmaceuticals, LLC</td>
<td class="formItem"></td>
<td class="formItem">840771732</td>
<td class="formItem">MANUFACTURE(63323-012)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 8/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>22cb8823-f453-4469-911e-49e3c92e99ef</div>
<div>Set id: c7fd585a-99b7-4309-b003-a6cbef05372c</div>
<div>Version: 1</div>
<div>Effective Time: 20120828</div>
</div>
</div> <div class="DistributorName">APP Pharmaceuticals, LLC</div></p>
</body></html>
